Long-term value of lecanemab to individuals and families.

ABSTRACT:

Introduction

An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation.

Methods

We used data from a nationally representative sample of middle aged and older Americans combined with data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) on AD progression and data on lecanemab treatment effects from Clarity AD clinical trials. We use dynamic microsimulation modeling to quantify the long-term health and economic value of lecanemab for persons living with AD and their care partners.

Results

We quantified five measures of value: quality of life of the persons living with AD and their care partners, medical

SUBMITTER: Tysinger B 

PROVIDER: S-EPMC12394178 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature